EGFR and breast carcinoma: The results from testing the SMKI plus CAT-SKL antioxidant combination on a set of molecularly diverse breast cancer-derived cell lines suggest that the treatment strategy could be of substantive benefit to patients if developed as a molecularly targeted therapy for TNBC that overexpresses EGFR.